Search Results
Dec 16, 2025, 08:00 ET Wealth Enhancement Announces Acquisition of Spectrum Wealth Management and Associated Tax Practice
financial professionals, and five support staff oversees more than $182 million in client assets and is led by Benjamin Ross Putman, CPA, CFP®, CEPA, PFS, CDFA, Founder and Principal, Sanaz Afshar, CPA, Joseph Reese, CPA, and Allan Ottens, CPA.
More news about: Wealth Enhancement
Dec 15, 2025, 23:55 ET Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
progression-free survival (CNS-PFS) of 15 months. The results of another Phase II clinical study of utidelone combined with bevacizumab for HER2-negative BCBM were published in JAMA Oncology in 2025 [2]. 47 subjects were recruited in the study, with a CNS-ORR of 42.6%, a median CNS-PFS of 10.6 months,
More news about: Biostar Pharma, Inc.
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
patients with ESR1-mutated diseaseIn all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a yearThese data were
More news about: Eli Lilly and Company
Dec 12, 2025, 10:47 ET Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
progression-free survival of 7.2 months in second-line MTAP-del pancreatic cancer patients, along with a 49% overall response rate and 9.1 months median PFS in a histology-selective cohort of 13 late-line difficult-to-treat cancer types. The company secured $225 million in gross proceeds from an October 2025
More news about: USA News Group
Dec 12, 2025, 08:27 ET ARIS MINING CLOSES ACQUISITION OF REMAINING 49% OF SOTO NORTE
gold project, where a new Preliminary Economic Assessment has been completed and a Prefeasibility Study is in progress. Following completion of the PFS, Toroparu will be positioned to advance toward construction.Aris Mining also owns the Soto Norte gold project, where a Prefeasibility Study has
More news about: Aris Mining Corporation
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
combination remained alive and progression-free compared to just 29.7% in the control arm, with a median PFS not yet reached in the treatment group versus 18.1 months in controls.Beyond PFS, the data demonstrated sustained benefits across secondary endpoints. Complete response rates of 81.8% were
More news about: DelveInsight Business Research, LLP
Dec 11, 2025, 06:00 ET IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trialTopline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United StatesSOUTH SAN
More news about: IDEAYA Biosciences, Inc.
Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
median progression-free survival (mPFS) was 15.2 months, with a 12-month PFS rate of 56.3%.In the CPS≥10 subgroup, the ORR was 83.3%, the DCR was 100%, the mDOR was 12.2 months; the mPFS was 15.9 months, with a 12-month PFS rate of 66.7%.In the CPS<10 subgroup, the ORR was 79.3%, the
More news about: Akeso, Inc.
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
SABCS demuestran que elacestrant en combinación con everolimus o con abemaciclib muestra un beneficio uniforme de supervivencia libre de progresión (PFS, por sus siglas en inglés), independientemente del estado de la mutación ESR1 en pacientes con CMM con ER+/HER2-, que experimentan progresión
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 06:15 ET Uranium Energy Corp Reports Results for First Quarter of Fiscal 2026
2025, targeting conversion of inferred to indicated uranium estimated resources to support the previously announced proposed pre-feasibility study ("PFS") for the world-class, high-grade Roughrider Project in the prolific Athabasca Basin of Saskatchewan, Canada.Launched United States
More news about: Uranium Energy Corp
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
saranno presentati al SABCS dimostrano che elacestrant, in combinazione con everolimus o con abemaciclib, mostra un beneficio costante in termini di PFS, indipendentemente dallo stato di mutazione ESR1 nei pazienti affetti da mBC ER+/HER2-, che presentano progressione della malattia durante la
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
聯合使用的安全性特徵，與每種藥物已知的安全性特徵一致。並未發現新的安全訊號。」將於 SABCS 發表的 ELEVATE 數據顯示，對於曾在接受內分泌治療 (ET) 後病情惡化（不論是否曾使用 CDK4/6 抑制劑）的 ER+/HER2- mBC 患者，elacestrant 聯合 everolimus 或 abemaciclib 均顯示出一致的 PFS 效益，且不受 ESR1 突變狀態影響。最新結果亦顯示，聯合療法的安全性與各標靶療法加上標準護理內分泌療法的已知安全性一致。第 2 期 mPFS（月）（95% 置信區間 [CI]），涵蓋所有患者及亞組
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
발표될 ELEVATE 데이터는 엘라세스트란트를 에베로리무스 또는 아베마시클립과 병용했을 때, ER+/HER2- mBC 환자 중 내분비 치료(ET)에서 질병이 진행된 환자(이전 CDK4/6 억제제 치료 경험 여부와 무관)에서 ESR1 돌연변이 여부와 무관하게 일관된 PFS 혜택이 나타났다. 이번 업데이트된 결과는 또한 병용 요법이 각 표적 치료제와 표준 내분비 치료제 요법의 알려진 안전성 프로파일과 일치함을 보여준다.2상 연구 mPFS(개월, 95% 신뢰구간): 전체 환자 및 하위군
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
patients with relapsed/refractory multiple myeloma who have received 1–3 prior lines of therapy. The primary endpoint is progression-free survival (PFS) and secondary endpoints include complete response or better (≥CR), overall response rate, minimal residual disease (MRD)-negativity (10⁻⁵ by next-generation
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
median follow-up of 28.1 months, the primary endpoint of IRC-assessed progression-free survival (PFS) was significantly improved with pirtobrutinib compared to BR (HR=0.20 [95% CI, 0.11–0.37]; p<0.0001). PFS results favored pirtobrutinib across all pre‑specified subgroups, including those with high-risk
More news about: Eli Lilly and Company
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
PTCL) achieved an objective response rate (ORR) of 53.8% and a complete response (CR) rate of 46.1%. Median progression-free survival (PFS) was 37.9 months and the 2-year PFS rate was 58.3%. The research findings validated golidocitinib's long-lasting efficacy and tolerability in the U.S. patient population.
More news about: Dizal Pharmaceutical
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
control group.The ivonescimab-based regimen met the primary PFS endpoint versus the tislelizumab-based regimen, delivering a decisive, strongly positive outcome with both statistical significance and clear clinical benefit. PFS was substantially prolonged with ivonescimab plus chemotherapy compared
More news about: Akeso, Inc.
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
beobachtet."Die ELEVATE-Daten, die auf der SABCS vorgestellt werden, zeigen, dass Elacestrant in Kombination mit Everolimus oder Abemaciclib einen konsistenten PFS-Vorteil zeigt, unabhängig vom ESR1 Mutationsstatus bei Patientinnen mit ER+/HER2- mBC, die unter endokriner Therapie (ET) einen Krankheitsfortschritt
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
observed."The ELEVATE data to be presented at SABCS demonstrate that elacestrant in combination with everolimus or with abemaciclib shows a consistent PFS benefit, irrespective of ESR1 mutation status in patients with ER+/HER2- mBC, who experience disease progression on endocrine therapy (ET), with
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
observed."The ELEVATE data to be presented at SABCS demonstrate that elacestrant in combination with everolimus or with abemaciclib shows a consistent PFS benefit, irrespective of ESR1 mutation status in patients with ER+/HER2- mBC, who experience disease progression on endocrine therapy (ET), with
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
clinical benefit.Across the 400–1200 μg/kg range, the 12-month PFS rate was 61.2% (median follow-up: 9.6 months). At 400 μg/kg (n=11), median follow-up reached 13.1 months, with a 12-month PFS rate of 56.8%.Executive CommentaryDr. Charles
More news about: Leads Biolabs
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
had R-ISS stage III with a triple-hit. 4 patients had extramedullary disease.With a median follow-up of 27.04 months, the median PFS was not reached. The PFS rates at 12, 18 and 24 months were 87.5%, 80.2% and 74.5%, respectively. All patients achieved MRD negativity within 1 month, and 80% of
More news about: IASO Bio
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
months, respectively. Among all subgroups, the largest PFS effect size was observed in the treatment-naïve subgroup, which had the longest follow-up at this data cut, with a 76% reduction in the risk of disease progression or death. A formal PFS analysis testing for superiority is planned at a future
More news about: Eli Lilly and Company
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
as well, showing 18-month progression-free survival (PFS) rates of 86.9% in the pirtobrutinib arm and 82.3% in the ibrutinib arm. Preliminary results suggest treatment-naive participants saw the most pronounced benefit for this endpoint."The PFS is still a little bit immature at this point, but
More news about: American Society of Hematology
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
CARVYKTI® as early as second line and 59 of those patients had standard-risk cytogenetics.1 At a median follow-up of 33.6 months, the 30-month PFS rate among the standard-risk patients in the as-treated population appeared to plateau at 80.5 percent (95 percent CI, 67.2–88.8) following a single
More news about: Johnson & Johnson